1. Generics Bulletin

Bill & Melinda Gates Foundation Commits $120m For Molnupiravir In Lower-Income Countries

Foundation Partners With Merck & Co On Developing Generic Versions Of Molnupiravir

 
• By Akriti Seth

The Bill & Melinda Gates Foundation has extended a financial commitment of up to $120m to secure a dedicated, low-cost supply of generic molnupiravir to lower-income countries. The Gates Foundation is looking to “significantly reduce the time it takes for a new drug to reach low-income countries after it becomes available in high-income markets.”

Gates Foundation
The Bill & Melinda Gates Foundation called on other donors to mobilize as well • Source: Alamy

As a part of its COVID-19 response effort, the Bill & Melinda Gates Foundation has committed up to $120m to support the development and manufacturing of generic versions of the investigational antiviral drug, molnupiravir, for lower-income countries.

Citing data reported by Merck & Co, the Foundation said that “molnupiravir, a broad-spectrum antiviral, can cut the risk of serious disease and death due to COVID-19 by half

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”